187 related articles for article (PubMed ID: 34556703)
1. Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer.
Presa D; Khurram SA; Zubir AZA; Smarakan S; Cooper PA; Morais GR; Sadiq M; Sutherland M; Loadman PM; McCaul J; Shnyder SD; Patterson LH; Pors K
Sci Rep; 2021 Sep; 11(1):18930. PubMed ID: 34556703
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents.
Bart AG; Morais G; Vangala VR; Loadman PM; Pors K; Scott EE
Drug Metab Dispos; 2022 Jan; 50(1):49-57. PubMed ID: 34607808
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.
Sutherland M; Gill JH; Loadman PM; Laye JP; Sheldrake HM; Illingworth NA; Alandas MN; Cooper PA; Searcey M; Pors K; Shnyder SD; Patterson LH
Mol Cancer Ther; 2013 Jan; 12(1):27-37. PubMed ID: 23033491
[TBL] [Abstract][Full Text] [Related]
4. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.
Travica S; Pors K; Loadman PM; Shnyder SD; Johansson I; Alandas MN; Sheldrake HM; Mkrtchian S; Patterson LH; Ingelman-Sundberg M
Clin Cancer Res; 2013 Jun; 19(11):2952-61. PubMed ID: 23589180
[TBL] [Abstract][Full Text] [Related]
5. The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells.
Ruparelia KC; Lodhi S; Ankrett DN; Wilsher NE; Arroo RRJ; Potter GA; Beresford KJM
Bioorg Med Chem Lett; 2019 Jun; 29(11):1403-1406. PubMed ID: 30935796
[TBL] [Abstract][Full Text] [Related]
6. Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.
Sheldrake HM; Travica S; Johansson I; Loadman PM; Sutherland M; Elsalem L; Illingworth N; Cresswell AJ; Reuillon T; Shnyder SD; Mkrtchian S; Searcey M; Ingelman-Sundberg M; Patterson LH; Pors K
J Med Chem; 2013 Aug; 56(15):6273-7. PubMed ID: 23844629
[TBL] [Abstract][Full Text] [Related]
7. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
Lee D; Perez P; Jackson W; Chin T; Galbreath M; Fronczek FR; Isovitsch R; Iimoto DS
Bioorg Med Chem Lett; 2016 Jul; 26(14):3243-3247. PubMed ID: 27265259
[TBL] [Abstract][Full Text] [Related]
8. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
[TBL] [Abstract][Full Text] [Related]
9. Diaryl triazenes inhibit cytochrome P450 1A1 and 1B1 more strongly than aryl morpholino triazenes.
Moran R; Nakamura R; Isovitsch R; Iimoto D
Bioorg Med Chem Lett; 2022 Mar; 59():128570. PubMed ID: 35063631
[TBL] [Abstract][Full Text] [Related]
10. Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors.
Choong E; Guo J; Persson A; Virding S; Johansson I; Mkrtchian S; Ingelman-Sundberg M
PLoS One; 2015; 10(4):e0122820. PubMed ID: 25844926
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one.
Ciolino HP; MacDonald CJ; Yeh GC
Cancer Res; 2002 Jul; 62(13):3685-90. PubMed ID: 12097275
[TBL] [Abstract][Full Text] [Related]
12. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
[TBL] [Abstract][Full Text] [Related]
13. Differential Effects of Sunitinib on the Expression Profiles of Xenobiotic-Metabolizing Enzymes and Transporters in Rat Liver and Kidneys.
Korashy HM; Ansari MA; Maayah ZH; Imam F; Raish M; Attafi IM; Alharbi NO; Moraished BA
Basic Clin Pharmacol Toxicol; 2016 Aug; 119(2):173-83. PubMed ID: 26797788
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2W1 (CYP2W1) - ready for use as the biomarker and drug target for cancer?
Pan Y; Ong EC
Xenobiotica; 2017 Oct; 47(10):923-932. PubMed ID: 27690753
[TBL] [Abstract][Full Text] [Related]
15. CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor.
Zhu J; Wang P; Li F; Lu J; Shehu AI; Xie W; McMahon D; Ma X
Biochem Pharmacol; 2018 Dec; 158():174-184. PubMed ID: 30342022
[TBL] [Abstract][Full Text] [Related]
16. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.
Tan BS; Tiong KH; Muruhadas A; Randhawa N; Choo HL; Bradshaw TD; Stevens MF; Leong CO
Mol Cancer Ther; 2011 Oct; 10(10):1982-92. PubMed ID: 21831963
[TBL] [Abstract][Full Text] [Related]
17. Relative effect potency estimates of dioxin-like activity for dioxins, furans, and dioxin-like PCBs in adults based on cytochrome P450 1A1 and 1B1 gene expression in blood.
Wimmerová S; van den Berg M; Chovancová J; Patayová H; Jusko TA; van Duursen MB; Palkovičová Murínová Ľ; Canton RF; van Ede KI; Trnovec T
Environ Int; 2016 Nov; 96():24-33. PubMed ID: 27588699
[TBL] [Abstract][Full Text] [Related]
18. Nitidine Chloride-Induced CYP1 Enzyme Inhibition and Alteration of Estradiol Metabolism.
Mao X; Wang J; Wang Q; Yang L; Li Y; Lin H; Peng Y; Zheng J
Drug Metab Dispos; 2019 Aug; 47(8):919-927. PubMed ID: 31147316
[TBL] [Abstract][Full Text] [Related]
19. Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.
Wang Z; Chen Y; Drbohlav LM; Wu JQ; Wang MZ
J Biomol Screen; 2016 Dec; 21(10):1090-1099. PubMed ID: 28139960
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons.
Shimada T; Guengerich FP
Chem Res Toxicol; 2006 Feb; 19(2):288-94. PubMed ID: 16485905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
